Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 288
---
 amount under their respective portion of the 2020 CLA, up to an additional
aggregate amount of $340,000, or the October 2024 Addendum, so that the 2020 CLAs shall bear interest at 8% per annum until maturity commencing
as of July 1, 2024 with respect to non-participating lenders and March 31, 2025 with respect to participating lenders. In addition, pursuant
to the October 2024 Addendum, upon the occurrence of an initial public offering based on a pre money valuation of $5.15 million, the 2020
CLAs shall be automatically converted into 243,955 Ordinary Shares and the Additional Amount in addition to the Risk Premium (each as
defined therein) shall be automatically converted into 221,456 Ordinary Shares, which will occur upon the completion of this offering.
As of November 20, 2024, the Company received $337,500 out of the $450,000 proceeds.

In September 2021, we entered
into several convertible loan agreements entered into in September 2021, or the 2021 CLAs, pursuant to which we obtained a convertible
loan in the aggregate amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the
Company of the same class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 35,354 Ordinary
Shares and the warrants granted thereunder expired in full in December 2023.

Between October 2024 and
November 2024, we entered into Bridge Loans, pursuant to which we obtained a bridge loan from certain lenders, including certain related
parties. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans have been extended until August 31, 2025 and
shall bear interest at 8% per annum until maturity commencing as of September 1, 2024. Furthermore, upon the occurrence of a Qualifying
IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective
loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares
during the first five trading days following the consummation of such initial public offering. As of January 15, 2025, the